AIDS Activists Say New HIV Treatment Guidelines Could Revolutionize HIV Care for People With AIDS
Maximal HIV Suppression becomes the Goal of Antiretroviral Therapy Unequal Access to Care Still Hinders Treatment Advances Members of the Treatment Action Group (TAG), a non-profit AIDS research and treatment advocacy group in New York City, offered strong praise for…
New Drug Dilemmas
Scientific and Regulatory Issues in the Era of Antiretrovirai Polytherapy and a Viral Load-Driven Standard of Care (Version 0.5) A Report to the FDA Antiviral Drugs Advisory Committee 14 July 1997 by Spencer Cox, Paul Dietz, Mark Harrington & Theo…
It’s Time to Change the Standard of Care For People With AIDS
ACTG 320 Proves that Indinavir and 3TC, when Added to AZT, Reduce AIDS and Death by Half when Compared with AZT and 3TC without Indinavir in HIV-Positive Individuals with Fewer than 200 CD4 Cells and Over Three Months of AZT…
Viral Load in Vancouver: A Report from the 11th International Conference on AIDS
A Report from the 11th International Conference on AIDS Vancouver, British Columbia, 8-11 July 1996 By Mark Harrington From the Introduction The year 1996 has brought a sea change in AIDS research and treatment. Three major factors have contributed to…
Access Versus Answers
From 1996 by Mark Harrington After Berlin, no one could credibly believe that AIDS drug development was on track. Indeed, it looked likely that the various initiatives AIDS activists had worked with FDA, NIH and industry to develop were actually…
The Wasting Report: Current Issues in Research and Treatment of HIV-Associated Wasting and Malnutrition
Current Issues in Research and Treatment of HIV-Associated Wasting and Malnutrition by Tim Horn & David Pieribone July 1996 From the Introduction Wasting syndrome can be a chronic and deadly manifestation of HIV. Multiple studies demonstrate that progressive weight loss…
Position Paper on Accelerated Approval for INVIRASE Brand Saquinavir
by Mark Harrington 7 November 1995 In September, 1994, the Treatment Action Group spelled out the following conditions as necessary for our support of an accelerated NDA for an HIV protease inhibitor: Adequate and well-controlled clinical endpoints studies are well…